Chemical Namedostarlimab-gxly
Dosage FormInjection (intravenous; 500 mg/10 mL (50 mg/mL))
Drug ClassMonoclonal antibodies
SystemFemale reproductive
CompanyGlaxoSmithKline plc
Approval Year2021


  • Indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
Last updated on 4/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Jemperli (dostarlimab-gxly) Prescribing Information2021GlaxoSmithKline LLC, Philadelphia, PA